Cancer Family
Esophageal Neoplasm
CI-CAN-00000174Explore in graph →
Non-malignant555 active trials6 approved drugs12 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000174Explore in graph →
Clinical trials
2,208 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05504265 | Perioperative Analgesia Modes in Minimally Invasive Esophagectomy | unknown | Phase 2 / Phase 3 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 |
| clinicaltrials |
| NCT05830097 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 260 | Coherent Biopharma (Hefei) Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06569459 | Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06498752 | MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer | unknown | Phase 2 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06512428 | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 138 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06464614 | Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. | unknown | Phase 2 | 54 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT05490719 | A Phase II Study of CRT Combined With QL1706 in ESCC Patients | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04159974 | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus(RICE) | unknown | Phase 2 | 56 | University of CologneOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06403878 | Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer | unknown | Phase 2 | 68 | Sichuan UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06398405 | A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer | unknown | Phase 2 | 72 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06392971 | Deep-sea Fish Oil for Prevention of Acute Radiation-induced Esophagitis | unknown | Phase 2 | 120 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT04776590 | Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer(CRISEC) | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06231680 | Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) | unknown | Phase 2 | 132 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 29, 2024 | clinicaltrials |
| NCT04844385 | Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 124 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05743504 | Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | unknown | Phase 1 / Phase 2 | 32 | National Taiwan University HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06198465 | Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma | unknown | Phase 2 | 24 | Xijing HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT02037048 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | unknown | Phase 2 | 63 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05626569 | Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06186609 | PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC | unknown | Phase 2 | 68 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT05512520 | Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma(EC-CRT-003)(EC-CRT-003) | unknown | Phase 2 | 126 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05376423 | To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for Recurrence | unknown | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06078657 | IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC) | unknown | Phase 2 | 46 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06055166 | A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors | unknown | Phase 2 | 120 | Chongqing University Cancer HospitalOTHER | 0 | Sep 26, 2023 | clinicaltrials |
| NCT05990231 | Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy | unknown | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06010212 | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT05996484 | Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma | unknown | Phase 2 | 25 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Aug 21, 2023 | clinicaltrials |
| NCT05281003 | Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)(HYPERION) | unknown | Phase 2 | 128 | Fudan UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05896787 | Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) | unknown | Phase 2 | 45 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05866510 | Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer | unknown | Phase 2 | 47 | Peking UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05038813 | Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC) | unknown | Phase 2 | 46 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05865132 | Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction | unknown | Phase 2 | 30 | AIPING ZHOUOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05833971 | Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 43 | Guangzhou Institute of Respiratory DiseaseOTHER | 0 | Apr 27, 2023 | clinicaltrials |
| NCT05828381 | Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer | unknown | Phase 2 | 33 | Fujian Medical University Union HospitalOTHER | 0 | Apr 25, 2023 | clinicaltrials |
| NCT05818982 | To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC | unknown | Phase 2 | 72 | Peking UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05817201 | Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy | unknown | Phase 2 / Phase 3 | 60 | Taizhou HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04389177 | Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) | unknown | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05791136 | Immunotherapy After Radiotherapy in Elderly ESCC(TREE) | unknown | Phase 2 | 30 | The Central Hospital of Lishui CityOTHER | 0 | Mar 30, 2023 | clinicaltrials |
| NCT05777707 | Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma | unknown | Phase 1 / Phase 2 | 89 | Beijing Friendship HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05323890 | Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma. | unknown | Phase 2 | 15 | Shandong Cancer Hospital and InstituteOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05163483 | Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer | unknown | Phase 2 | 87 | Ruihua XuOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05650216 | Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC(NICE-RT) | unknown | Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05636150 | A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 48 | Peking Union Medical College HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05637268 | Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 23 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05619016 | [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors | unknown | Phase 2 | 72 | Karolinska University HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05386056 | Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 54 | Peking UniversityOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05596890 | Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients(PICCRT) | unknown | Phase 2 | 50 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05594914 | AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 47 | The First Affiliated Hospital of University of South ChinaOTHER | 0 | Oct 26, 2022 | clinicaltrials |
| NCT05552651 | Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 40 | Tao JiangOTHER | 0 | Sep 23, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Mar 20, 2025source: clinicaltrials